Healthcare Sales & Marketing Network News: laquinimod

Searching News Database: laquinimod

HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Biopharmaceuticals Neurology

HSMN NewsFeed - 23 Jul 2008
Tomas Leanderson appointed new President & CEO for Active Biotech
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Biopharmaceuticals Neurology

HSMN NewsFeed - 7 Jun 2007
Teva and Active Biotech to Initiate Pivotal Phase III Trial Program of Oral Laquinimod for Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 1 May 2007
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology

Return to NewsFeed

Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 3 additional stories matching:
laquinimod
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.